More than 2.5 million bottles of a common prescription steroid eye drop sit in medicine cabinets across the U.S. They shouldn’t. Lupin Pharmaceuticals initiated the recall in early June. The FDA classified it Class II by month’s end. The trigger? A foreign substance in some units. No injuries reported so far. Yet the scale raises fresh questions about oversight of overseas production.
The product is prednisolone acetate ophthalmic suspension, 1%. Doctors prescribe it after eye surgery. They use it for injuries, allergies and inflammatory conditions. It reduces swelling and redness. Patients apply it directly to the eye. That route bypasses many natural defenses. Any contaminant gains easy access.
Lupin Limited manufactures the drops in Pithampur, India. Its U.S. arm, Lupin Pharmaceuticals, distributes them nationwide. The recall covers 5-milliliter, 10-milliliter and 15-milliliter bottles. Specific NDC codes include 70748-332-02, 70748-332-03 and 70748-332-04. Dozens of lot numbers carry expiration dates from July 31, 2026, through March 31, 2028. Exact affected lots appear in the FDA enforcement report.
The FDA defines a Class II recall as one in which use of the product may cause temporary or medically reversible adverse health consequences. Or the probability of serious adverse health consequences remains remote. Class I involves reasonable probability of serious injury or death. Class III suggests little chance of harm. This one sits in the middle. Serious enough to act. Not catastrophic on paper.
Contamination Discovery and Immediate Fallout
A consumer found foreign material inside a sealed vial. That single report set the recall in motion. Lupin notified customers by letter on June 4. The agency upgraded the classification June 30. Recall number D-0655-2026 now appears in FDA databases. The precise nature of the substance stays undisclosed. Tests continue.
Patients face a practical dilemma. Many rely on these drops for ongoing treatment. The FDA says stop using recalled product immediately. But don’t quit steroid therapy cold. Contact a pharmacist or doctor first for a replacement. Reports of problems go to Lupin at 1-800-399-2561 or FDA MedWatch at 1-800-FDA-1088.
Healthcare providers received the same alert. They must check inventory. Quarantine affected stock. Notify patients. The volume – 2,530,182 bottles – suggests wide distribution through pharmacies and hospitals. Checking every bottle proves tedious. Many packages hold multiple units. Consumers compare lot numbers near the expiration date against the full FDA list.
And here lies the tension. Eye medications demand sterility. Foreign particles introduce infection risk, irritation or worse. Past outbreaks tied to contaminated drops caused blindness and deaths. Regulators tightened rules afterward. Yet incidents continue. Gizmodo first highlighted the scale and noted Lupin’s manufacturing location. Similar recalls hit other firms in recent years over sterility lapses or impurities.
Lupin has history. In 2022 it recalled blood pressure medicine quinapril over nitrosamine impurities. That class of compounds carries long-term cancer concerns. The company did not respond to requests for comment in multiple reports. Silence leaves physicians and patients filling information gaps themselves.
Recent coverage adds urgency. USA Today detailed the NDCs and lot breadth while stressing immediate discontinuation. Fox Business explained the Class II tier and noted the Indian plant origin. MassLive called it the second-highest risk level and listed contact numbers. These accounts, all published within the past day or two, show the story spreading fast through consumer and health outlets.
Industry watchers see patterns. Overseas facilities supply much of the U.S. generic market. FDA inspections occur. But distance and volume complicate enforcement. Foreign material can stem from packaging defects, raw material impurities or process deviations. Without public details on root cause, prevention stays elusive.
Prednisolone drops treat common ailments. Millions use similar products yearly. A recall this size disrupts care. Pharmacies scramble for substitutes. Patients worry about safety even with non-recalled stock. Trust erodes when routine medications trigger alarms.
So what now? Regulators will review Lupin’s corrective plan. The company must investigate. Implement fixes. Re-inspect lines. Future shipments face extra scrutiny. For now, the 2.5 million bottles represent both a contained problem and a signal. Manufacturing quality cannot slip. Eyes are too vulnerable. Patients too dependent.
The episode fits larger trends. Recall numbers for ophthalmic products climbed in recent years. Sterility failures dominate headlines. This case involves visible foreign matter rather than invisible microbes. The distinction matters less to someone applying drops daily. Any anomaly feels threatening.
Physicians advise checking cabinets. Compare lot numbers. Return affected product. Seek alternatives only through professionals. Most users will never experience harm. The remote risk still justifies action. Better to pause treatment under guidance than risk complications.
Lupin’s recall won’t be the last. But each one sharpens focus on supply chain controls, testing protocols and rapid response. The FDA’s swift classification shows the system works at notification stage. The harder part remains preventing the next foreign substance from reaching pharmacy shelves.
WebProNews is an iEntry Publication